Anixa Biosciences (ANIX) Research & Development (2010 - 2026)
Anixa Biosciences' (ANIX) quarterly Research & Development came in at $1.3 million in Q2 2026, down 4.84% YoY from $1.3 million in Q2 2025, and up 10.16% on a QoQ basis from $1.1 million in Q4 2025.
Anixa Biosciences (ANIX) Research & Development (2010 - 2026) Analysis & Trends
Anixa Biosciences (ANIX) has 14 years of Research & Development data on file, last reported at $1.3 million in Q2 2026.
- Quarterly Research & Development fell 4.84% year-over-year to $1.3 million in Q2 2026, while the trailing twelve-month figure through Apr 2026 was $4.8 million (down 23.87% YoY) and the FY2025 annual result came in at $5.1 million, down 20.72% from the prior year.
- Research & Development rose to $1.3 million in Q2 2026, from $1.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $1.9 million in Q3 2024 to a low of $998000.0 in Q2 2023.
- A 5-year average of $1.4 million and a median of $1.4 million in 2022 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 121.98% — and 2025, when it slumped 45.19%.
- Tracing ANIX's Research & Development over 5 years: stood at $1.7 million in 2022, then fell by 4.15% to $1.6 million in 2023, then decreased by 8.61% to $1.5 million in 2024, then declined by 22.63% to $1.1 million in 2025, then increased by 10.16% to $1.3 million in 2026.
- The last three Research & Development figures came in at $1.3 million (Q2 2026), $1.1 million (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 97.90 Mn |
| 10 | Anixa Biosciences | 122.95 Mn | 122.95 Mn | - | 1.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.26 Mn |
| Oct 31, 2025 | 1.14 Mn |
| Jul 31, 2025 | 1.06 Mn |
| Apr 30, 2025 | 1.32 Mn |
| Jan 31, 2025 | 1.55 Mn |
| Oct 31, 2024 | 1.48 Mn |
| Jul 31, 2024 | 1.93 Mn |
| Apr 30, 2024 | 1.65 Mn |
| Jan 31, 2024 | 1.35 Mn |
| Oct 31, 2023 | 1.62 Mn |
| Jul 31, 2023 | 1.09 Mn |
| Apr 30, 2023 | 998,000.00 |
| Jan 31, 2023 | 1.07 Mn |
| Oct 31, 2022 | 1.69 Mn |
| Jul 31, 2022 | 1.45 Mn |
| Apr 30, 2022 | 1.74 Mn |
| Jan 31, 2022 | 1.84 Mn |
| Oct 31, 2021 | 2.17 Mn |
| Jul 31, 2021 | 2.17 Mn |
| Apr 30, 2021 | 1.02 Mn |